Project Grant R01CA292799
Award Date 9/23/25
Completion Date 8/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $215,985 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University is for a pilot study to sequence exosomal RNA from the blood and urine of 50 patients with renal cell carcinoma. The objective is to identify early biomarkers for therapeutic response to the immune checkpoint inhibitor combination of nivolumab and ipilimumab. The study will analyze changes in the exosomal proteins and RNA,...
- The University of California, San Diego (UCSD) was awarded a $444,952 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to conduct research exploring the impact of base deaminase deregulation on precancer evolution. The 5-year grant, which commenced on December 1, 2024, aims to elucidate the relative roles of APOBEC3C and ADAR1 deaminases in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
- The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...
- This federal Project Grant award of $988,224.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the University of California, San Diego's research program focused on advancing treatment for head and neck cancer patients with competing health risks through multi-center randomized trials. The principal investigator has extensive experience leading national clinical trials through the NRG Oncology cooperative group and serving as co-chair of the NCI Head and...
- The University of California, San Diego (UCSD) was awarded a $1,031,651 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The grant, awarded on February 1, 2025, aims to optimize the in vitro production, cryopreservation, and biobanking of "cargocytes" - a novel therapeutic delivery system designed to transport therapeutic...
- The University of Southern California received a $426,828 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on August 15, 2025. The grant supports research to develop DNA methylation markers for early detection and monitoring of tumor burden in bladder cancer. The research aims to identify non-invasive biomarkers in urine samples that can detect bladder cancer recurrence at an earlier stage and monitor tumor response during treatment. This...